SymBio Pharmaceuticals Limited (TYO:4582)
65.00
-1.00 (-1.52%)
Aug 21, 2026, 3:30 PM JST
SymBio Pharmaceuticals Revenue
SymBio Pharmaceuticals had revenue of 235.54M JPY in the quarter ending June 30, 2026, a decrease of -38.34%. This brings the company's revenue in the last twelve months to 1.13B, down -37.71% year-over-year. In the year 2025, SymBio Pharmaceuticals had annual revenue of 1.31B, down -46.70%.
Revenue (ttm)
1.13B
Revenue Growth
-37.71%
P/S Ratio
4.39
Revenue / Employee
12.42M
Employees
91
Market Cap
4.96B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.31B | -1.15B | -46.70% |
| Dec 31, 2024 | 2.45B | -3.14B | -56.13% |
| Dec 31, 2023 | 5.59B | -4.42B | -44.15% |
| Dec 31, 2022 | 10.01B | 1.75B | 21.21% |
| Dec 31, 2021 | 8.26B | 5.27B | 176.42% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Ain Holdings | 647.83B |
| Ohki Healthcare Holdings | 363.02B |
| Qol Holdings | 292.95B |
| YAKUODO HOLDINGS | 168.44B |
| Medical System Network | 134.23B |
| Satudora Holdings | 100.57B |
| Pharmarise Holdings | 69.51B |
| Astena Holdings | 67.21B |